Fusion Proteins Or Polypeptides Patents (Class 435/69.7)
  • Patent number: 11370821
    Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
    Type: Grant
    Filed: October 21, 2021
    Date of Patent: June 28, 2022
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
  • Patent number: 11365224
    Abstract: Three-dimensional, living, self-regenerative structures of predetermined geometry comprising solidified print material comprising a biofilm of Bacillus subtilis comprise a TasA-R protein, wherein R is a recombinant, heterologous functional group, wherein the TasA-R provides a preferably tunable physiochemical property like viscosity, reactivity, affinity as a function of the R group.
    Type: Grant
    Filed: February 7, 2021
    Date of Patent: June 21, 2022
    Assignee: ShanghaiTech University
    Inventors: Chao Zhong, Jiaofang Huang, Suying Liu, Chen Zhang
  • Patent number: 11319568
    Abstract: The present invention relates to methods of modulating the mannose content of recombinant proteins.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: May 3, 2022
    Assignee: AMGEN INC.
    Inventors: Jian Wu, Sean Davern, Simina Crina Petrovan, Michael Charles Brandenstein, Katherine Rose Lindahl, Shawn Erik Lillie
  • Patent number: 11300564
    Abstract: Methods, devices, systems, and apparatuses are provided for the image analysis of measurement of biological samples.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: April 12, 2022
    Assignee: Labrador Diagnostics LLC
    Inventors: Elizabeth A. Holmes, Chinmay Pangarkar, Timothy Smith, Karan Mohan, Daniel Young, James Wasson, Samartha Anekal
  • Patent number: 11261460
    Abstract: The present invention provides compositions and methods of use pertaining to rAAV-mediated delivery of therapeutically effective molecules for treatment of diseases such as Pompe disease. These compositions in combination with various routes and methods of administration result in targeted expression of therapeutic molecules in specific organs, tissues and cells.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: March 1, 2022
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Barry John Byrne, Darin J. Falk, Christina Pacak, Lara Robert DeRuisseau, Cathryn Mah, David D. Fuller
  • Patent number: 11237176
    Abstract: The invention provides an infrared assay which allows the secondary structure analysis of alpha-synuclein from complex fluids like serum, blood plasma or cerebrospinal fluid without prior isolation, concentration or pretreatment. The secondary structure profile provides an indication of the proportion of alpha-synuclein in aggregated form and/or extent of aggregation of alpha-synuclein in aggregated form.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: February 1, 2022
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventor: Robin Barbour
  • Patent number: 11230726
    Abstract: This invention is intended to identify a gene cluster involved in biosynthesis of a cyclic peptide compound produced by a filamentous fungus of the Curvularia species and to establish a system for synthesizing such cyclic peptide compound. The gene is composed of a first module to a tenth module and encodes a protein having activity of synthesizing a nonribosomal peptide constituting a basic peptide backbone of a cyclic peptide compound produced by a filamentous fungus of the Curvularia species.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: January 25, 2022
    Assignees: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, TOHOKU UNIVERSITY, KUMIAI CHEMICAL INDUSTRY CO., LTD.
    Inventors: Takashi Kubo, Masayuki Machida, Maiko Umemura, Keietsu Abe, Akira Yoshimi, Tomonori Fujioka, Shigenari Yamaguchi, Kiyoshi Kawai
  • Patent number: 11219694
    Abstract: The subject matter described herein is directed to methods of modifying the micro-environment of a target cell or The methods comprise systemically administering to a subject a composition comprising a vector, wherein the vector comprises a construct for the expression of a trap in the target cell, wherein the trap is expressed in the target cell thereby modifiying the micro-environment. Also described herein are methods of reducing metastasis of a cancer comprising, systemically administering to a subject suffering from the cancer, a composition comprising a vector, wherein the vector comprises a construct for the expression of a trap, wherein the trap is delivered to and then expressed in tissue susceptible to metastasis, wherein metastasis of the cancer to the tissue is reduced. Compositions for carrying out the methods are also described.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: January 11, 2022
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Leaf Huang, Tyler Goodwin, Rihe Liu, Lei Miao
  • Patent number: 11202841
    Abstract: A multi-chromophore virus particle is constructed by covalent binding of chromophores and provides super-radiant behavior. A virus-enabled targeted vector is provided for imaging with qualitatively different optical emission properties from state-of-the-art agents. Bright emission is obtained through quantum coherence, which in turn is facilitated by the symmetry of the virus shell. In an exemplary embodiment the targeted vector is used in laser-guided surgery, specifically for the treatment of in brain cancer.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: December 21, 2021
    Assignee: THE TRUSTEES OF INDIANA UNIVERSITY
    Inventor: Bogdan Dragnea
  • Patent number: 11198859
    Abstract: Provided are a recombinant polynucleotide encoding a polypeptide including a reporter moiety, a substrate moiety, and a destabilization moiety, a host cell including the same, and use thereof to measure the level of a protease by using the recombinant polynucleotide.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: December 14, 2021
    Assignee: MEDYTOX INC.
    Inventors: Hyun Ho Jung, Gi Hyeok Yang, Jun Ho Lee, Dong Kyu Lee, Young Rae Lee
  • Patent number: 11155600
    Abstract: A therapeutic composition is described that can be used for treating or prevention of diseases association with modulation of activity of human IL-1?. In certain aspects, the disclosed invention is based, on engineering of a heterodimeric protein assembly that is capable of binding to human IL-1? and attenuating its function. The heterodimeric protein assembly comprises extracellular portions of human IL1-R1 and of human IL-1RAcP, or their functional fragments. Each, the IL1-R1 portion and the IL-1RAcP portion, is fused to a distinct mutant of Fc portion of the human Ig Gamma-1. The two distinct Fc mutants in the heterodimeric protein assembly are engineered as to favor the heteromeric dimer formation between the two Fc mutants over any homomeric assembly. The therapeutic composition has been formulated for administration into humans and animals.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: October 26, 2021
    Inventors: Yan Lavrovsky, Ting Xu, Elena Batienko, Anna Krotkova, Vasily Ignatiev, Mikhail Samsonov, Alexey Repik
  • Patent number: 11136560
    Abstract: The present invention provides a pipecolic acid 4-hydroxylase protein exemplified by the following (A), (B), and (C), having activity to react with L-pipecolic acid in the presence of 2-oxoglutaric acid and iron(II) ions to produce trans-4-hydroxy-L-pipecolic acid, and a method for producing 4-hydroxy amino acid, which method comprises reacting the pipecolic acid 4-hydroxylase protein, cells containing the protein, a treated product of the cells, and/or a culture liquid obtained by culturing the cells, with ?-amino acid to produce 4-hydroxy amino acid: (A) a polypeptide comprising the amino acid sequence represented by SEQ ID NO:2, 4, 6, 8, 10, 12, 16, or 18; (B) a polypeptide comprising the amino acid sequence represented by SEQ ID NO:2, 4, 6, 8, 10, 12, 16, or 18 except that one or several amino acids are deleted, substituted, and/or added, and having pipecolic acid 4-hydroxylase activity; and (C) a polypeptide having an amino acid sequence that is not less than 80% identical to the amino acid sequence rep
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: October 5, 2021
    Assignee: API CORPORATION
    Inventors: Makoto Hibi, Jun Ogawa, Ryoma Miyake, Hiroshi Kawabata
  • Patent number: 11078467
    Abstract: The disclosure relates to the field of fusion proteins. In some aspects, the disclosure relates to artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes and uses thereof. In some aspects, the disclosure relates to corn-pounds produced by artificial cytochrome P450 enzymes.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: August 3, 2021
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Yousong Ding, Ran Zuo
  • Patent number: 11072788
    Abstract: The present invention relates to an expansin-agarase enzyme complex and a method of degrading agar by using the same. The use of the enzyme complex according to the present invention can efficiently degrade agar obtained from marine biomass, and thus can efficiently provide not only galactose or glucose, necessary for ethanol production, but also useful biologically active substances, such as diose, triose, and oligosaccharides.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: July 27, 2021
    Assignee: Korea University Research and Business Foundation
    Inventors: Sung Ok Han, Da-woon Jeong, Jeong-Eun Hyeon
  • Patent number: 11046952
    Abstract: Embodiments disclosed herein are directed to a new genetic perturbation and screening method that combines advantages of pooled perturbation with imaging assays for complex phenotypes. Specifically, the method may be used to screen pooled genomic perturbations to identify phenotypes and to identify perturbed genes at the single-cell level using optical barcodes. A major advantage offered by this approach is the ability to screen for any cellular phenotype that can be identified by high-resolution microscopy—including live-cell phenotypes, protein localization, or highly multiplexed expression profile and mRNA localization by RNA-FISH—in conjunction with a large array of genetic perturbations applied as a pool in a single test volume.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: June 29, 2021
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Paul Blainey, David Feldman
  • Patent number: 10961500
    Abstract: Cell culture media are provided herein as are methods of using the media for cell culture and protein production from cells.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: March 30, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Wei Xue, John Chen, Carolyn Scott, Theodore Loney, Nathaniel Golden
  • Patent number: 10928381
    Abstract: Provided herein are compositions and systems comprising engineered cells useful for the measurement of autophagy induction, maturation and flux in a high-throughput manner. In particular, provided herein are human embryonic kidney (HEK) cells that express the native autophagy substrate and marker protein LC3 fused to Dendra2, a photoconvertable fluorescent protein; this manipulation allows assessment of all three stages of autophagy (e.g., induction, maturation, and cargo degradation), noninvasively in living cells, without the need for protein overexpression that may interfere with autophagy activity.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: February 23, 2021
    Assignee: The Regents of the University of Michigan
    Inventors: Sami Barmada, Nathaniel Safren, Elizabeth Tank
  • Patent number: 10927342
    Abstract: The specification describes a composition comprising an improved eukaryotic cell culture medium, which can be used for the production of a protein of interest. Taurine can be added to the serum-free media or chemically-defined media to increase the production of a protein of interest. Methods for recombinantly expressing high levels of protein using the media compositions are included.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: February 23, 2021
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Amy S. Johnson, Meghan E. Casey, Shadia Oshodi, Shawn Lawrence
  • Patent number: 10899823
    Abstract: Some embodiments of the systems, methods and compositions provided herein relate to a compound protease. In some embodiments, the compound protease includes a protease domain and a cut site for another enzyme. In some embodiments, the compound protease includes an association domain. In some embodiments, the compound protease is part of a protein circuit.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: January 26, 2021
    Assignee: California Institute of Technology
    Inventors: Xiaojing Gao, Lucy S. Chong, Michael Elowitz, Mark William Budde, Matthew Sun-min Kim
  • Patent number: 10881718
    Abstract: Bifunctional conjugate compositions are provided comprising a Signal-1 moiety bound to a first polymer carrier, wherein the combined size of the Signal-1 moiety and the first polymer carrier is about 1 nanometer to about 500 nanometers; and a Signal-2 moiety bound to a second polymer carrier, wherein the combined size of the Signal-2 moiety and the second polymer carrier is about 1 nanometer to about 500 nanometers. In some embodiments, the Signal-1 moiety and the Signal-2 moiety are bound to the same polymer carrier. Associated methods are also provided.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: January 5, 2021
    Assignee: The University of Kansas
    Inventors: Cory Berkland, Joshua Sestak, Teruna J. Siahaan
  • Patent number: 10815517
    Abstract: Described is a method aiding in the assessment of the presence of cancer. The method uses the soluble DPPIV/seprase protein complex (DPPIV/seprase) as a universal marker of different cancer types. Measurement of DPPIV/seprase complex can, e.g., be used in the early detection or diagnosis of cancer or in the surveillance of patients who undergo surgery.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: October 27, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Magdalena Swiatek-de Lange, Johann Karl, Wolfgang Rollinger
  • Patent number: 10766945
    Abstract: The invention provides a fusion protein comprising, from N-terminus to C-terminus: a) a first portion of a Family B G-protein coupled receptor (GPCR) that comprises transmembrane helix (TM)-1, TM2 and TM3 of the GPCR; b) a stable protein domain; and c) a second portion of the GPCR comprising TM4, TM5, TM6 and TM7 of the GPCR. The invention also provides a method of crystallising a GPCR comprising providing the fusion protein of the invention and crystallising it to obtain crystals.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: September 8, 2020
    Assignee: Heptares Therapeutics Limited
    Inventors: Seyed Ali Jazayeri-Dezfuly, Fiona Hamilton Marshall
  • Patent number: 10745456
    Abstract: The invention provides combinatorial peptide or polypeptide libraries that can become membrane tethered once expressed in cells. The invention additionally provides methods for selecting peptide modulators (e.g., agonists) of GPCRs from the combinatorial libraries of the invention. The invention also provides novel GPCR polypeptide modulators, e.g., biased polypeptide agonists of the glucagon-like peptide 1 receptor (GLP-1R). The invention further provides methods of promoting insulin sensitivity, lowering blood glucose, and reducing body weight as well as methods for treating various diseases such as diabetes and obesity.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: August 18, 2020
    Assignee: The Scripps Research Institute
    Inventors: Richard A. Lerner, Hongkai Zhang, Patricia McDonald, Jia Xie, Emmanuel Sturchler, Philip Dawson
  • Patent number: 10731143
    Abstract: Methods for producing a trans-splicing intein-modified protease with enhanced solubility and regulating its activity are described. Intein-modified proteases having enhanced solubility and polynucleotides encoding the same are provided. Methods of storing trans-splicing proteases are also described.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: August 4, 2020
    Assignee: AGRIVIDA, INC.
    Inventors: R. Michael Raab, Binzhang Shen, Gabor Lazar
  • Patent number: 10711049
    Abstract: The present disclosure relates to a method for producing a TLR5 agonist protein. According to the present disclosure, the TLR5 agonist protein can be easily separated and purified after biotechnological production. In particular, the fusion partner used for separation and purification is effectively removed so as to minimize the possibility of inhibiting binding to TLR5 and inducing an immune response by the fusion partner.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: July 14, 2020
    Assignee: Korea Institute of Industrial Technology
    Inventors: Woo-Jong Lee, Sung-Gun Kim, Dong-Mok Lee, Hee-Kyung An, Chi-Min Choi
  • Patent number: 10702587
    Abstract: Methods and compositions for reducing one or more of triglyceride levels, total cholesterol levels and LDL cholesterol levels in a subject are provided. The methods include administering a fragment of ANGPTL8 to a subject having or at risk of developing elevated triglyceride levels, elevated total cholesterol levels and/or elevated LDL cholesterol levels.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: July 7, 2020
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Zhonghao Liu, Xunshan Ding
  • Patent number: 10695403
    Abstract: The present invention relates to an FGF19 polypeptide for use in increasing muscle fiber size in the treatment of muscle atrophy in a mammal.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: June 30, 2020
    Assignees: Universite Claude Bernard Lyon, Institut National de la Recherche Agronomique (INRA), Institut National de la Santè et de la Recherche Médicale (INSERM), Bergen Teknologioverforing AS
    Inventors: Emmanuelle Fouilloux-Meugnier, Hubert Vidal, Jérome Ruzzin
  • Patent number: 10669324
    Abstract: The present invention relates to a nucleic acid sequence which encodes a protein of SEQ ID NO: 1; a vector comprising said nucleic acid sequence and a host cell comprising said nucleic acid sequence or said vector. The present invention also relates to a protein obtained or obtainable by expression of said nucleic acid sequence or said vector in a host cell. Furthermore, the present invention relates to a protein encoded by a nucleic acid sequence of SEQ ID NO: 6. Additionally comprised by the present invention are pharmaceutical compositions and a method of manufacturing the same.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: June 2, 2020
    Assignee: SUPPREMOL GMBH
    Inventors: Peter Sondermann, Dominik Ter Meer, Thomas Pohl, Reno Winter, Uwe Jacob
  • Patent number: 10653752
    Abstract: Methods and compositions for the use of long-acting hematopoietic factor protein analogs for accelerating hematopoietic recovery in subjects who have been or will be exposed to radiation are disclosed.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: May 19, 2020
    Assignee: Bolder Bio Technology, Inc.
    Inventors: George N. Cox, Christie M. Orschell
  • Patent number: 10548921
    Abstract: Disclosed are compositions and methods related to rendering ineffective Th1 T cells resistant to the inhibitory cytokine milieu present in a cancer microenvironment. Tumor-specific T cells are modified to employ a chimeric receptor that binds inhibitory/suppressive cytokines and converts their intracellular consequences to a Th1 immunostimulatory/activating signal. The T cells employ a chimeric antigen receptor having exodomains for IL10, IL13 and/or IL4 fused with the signal transducing endodomains for IL2 and/or IL7.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: February 4, 2020
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Ann Marie Leen, Juan F. Vera
  • Patent number: 10544198
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: January 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang, Ganesh A. Kolumam, Wyne P. Lee
  • Patent number: 10464979
    Abstract: Disclosed herein are FGF23 c-tail fusion proteins, pharmaceutical compositions comprising the FGF23 c-tail fusion proteins, and methods of treatment using the FGF23 c-tail fusion proteins. This application discloses fusion proteins comprising a FGF-23 c-tail protein fused to a heterologous amino acid sequence, wherein said fusion protein modulates serum phosphate levels but does not substantially modulate serum 1, 25 VitD levels. In some embodiments, the FGF-23 c-tail protein is fused to the heterologous amino acid sequence via a linker. This invention also encompasses vectors comprising the nucleic acids disclosed herein, and a host cell comprising the vector or polynucleotides encoding the proteins of the invention.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: November 5, 2019
    Assignees: New York University, Pfizer Inc.
    Inventors: Moosa Mohammadi, Regina Goetz, Jeanne Sue Magram, Kristen Leigh Johnson
  • Patent number: 10435451
    Abstract: The present invention provides a fusion protein comprising a latency associated peptide (LAP), a pharmaceutically active agent and an amino acid sequence comprising a dimerization domain, wherein the LAP and the pharmaceutically active agent are connected by an amino acid sequence comprising a proteolytic cleavage site. Also provided are nucleic acids enclosing such fusion proteins, process for their preparation, pharmaceutical compositions, kits and uses thereof in medicine.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: October 8, 2019
    Assignee: Stealthyx Therapeutics Limited
    Inventors: Yuti Chernajovsky, Lisa Mullen, Gillian Adams, David James Gould, Hawzheen Muhammad
  • Patent number: 10414729
    Abstract: Dynamic nuclear polarization (DNP) agents are provided for DNP nuclear magnetic resonance of analytes. The DNP agents can have the structure A-X-L-R, where A is none or an amphiphilic group; X is a coupling group capable of site-specific binding with the analyte or, when A is an amphiphilic group, capable of site-specific binding with the amphiphilic group; L is a bond or a linker group; and R is a poly-radical group. The poly-radical can be a di-radical, a tri-radical, a tetra-radical, or a combination thereof. Methods of NMR measurement of an analyte comprising an NMR-detectable nucleus are provided. The methods can include the steps of providing a frozen sample containing the analyte and a DNP agent; applying radiation having a frequency that excites electron spin transitions in the DNP agent at an intensity to polarize the NMR-detectable nucleus; and detecting a signal from nuclear spin transitions in the NMR-detectable nucleus.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: September 17, 2019
    Assignee: NORTH CAROLINA STATE UNIVERSITY
    Inventors: Alexej I. Smirnov, Maxim Anatolyevich Voynov
  • Patent number: 10370424
    Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 6, 2019
    Assignee: Wyeth, LLC.
    Inventors: John Wozney, Howard Seeherman, Christopher Todd Brown
  • Patent number: 10336813
    Abstract: Disclosed is a fusion protein Slit2D2-HSA formed by fusion of a Slit2D2 polypeptide and a human serum albumin HSA, and use thereof for the manufacture of a medicament for prophylaxis and/or treatment of sepsis, and the said fusion protein Slit2D2-HSA retains the pharmacological activities of Slit2 in inhibition of neutrophil migration and treatment of sepsis, and has an improved stability, prolonged half-life and improved therapeutic effect of sepsis. Compared with protein of Slit2, the polypeptide of Slit2D2 has a smaller molecular weight which is much easier to be purified and separated in preparation and used in the development of drugs.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: July 2, 2019
    Assignee: ASCLEPIUS (SUZHOU) TECHNOLOGY COMPANY GROUP CO., LTD.
    Inventor: Huashun Li
  • Patent number: 10316081
    Abstract: The present disclosure is directed to humanized anti-C1q antibodies and methods of using them.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: June 11, 2019
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Patent number: 10301607
    Abstract: The present invention relates to novel methods of generating and screening for chimeric polypeptides, which can be used in the treatment and prophylaxis of pathogenic bacterial contamination, colonization and infection. The novel methods are based on random recombination of protein domains, and the chimeric polypeptides obtainable by the methods according to the invention are characterized in that they comprise at least one enzymatic active domain (EAD) and at least one cell binding domain (CBD). The present invention also relates to a library of chimeric polypeptides obtainable by the methods of the present invention.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: May 28, 2019
    Assignee: HYPHARM GMBH
    Inventors: Anna Scherzinger, Sonja Molinaro, Bernd Buchberger
  • Patent number: 10273303
    Abstract: Provided herein are monovalent antigen-binding constructs targeting EGFR and/or HER2. The monovalent antigen-binding constructs can include at least one antigen-binding polypeptide comprising a heavy chain variable domain, wherein the antigen-bind polypeptide specifically binds EGFR and/or HER2; and a heterodimeric Fc domain, the Fc domain comprising at least two CH3 domains, wherein the Fc domain is coupled, with or without a linker, to the antigen-binding polypeptide. Also provided are methods of making the constructs and methods of using the constructs.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: April 30, 2019
    Assignee: Zymeworks Inc.
    Inventors: Gordon Yiu Kon Ng, Peter Wing Yiu Chan, Grant Raymond Wickman
  • Patent number: 10208100
    Abstract: In one aspect, provided herein is a polypeptide comprising a modified angiopoietin receptor or fragment thereof, wherein the polypeptide binds preferentially to angiopoietin-2 compared to angiopoietin-1. Nucleic acid sequences encoding the polypeptide, as well as pharmaceutical uses of the polypeptide in treating diseases such as cancer and inflammation are also provided.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: February 19, 2019
    Assignee: UNITED KINGDOM RESEARCH AND INNOVATION
    Inventors: Nicolas Phillip James Brindle, Julian Edward Sale
  • Patent number: 10125197
    Abstract: The invention relates to a cytotoxic modular antibody with a molecular weight of up to 60 kD, specifically binding to a cell surface target with a binding affinity of Kd<10?8 M, a method of producing such antibody and its use as a therapeutic.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: November 13, 2018
    Assignee: F-STAR BIOTECHNOLOGISCHE FORSCHUNGS-UND ENTWICKLUNGSGES.M.B.H
    Inventors: Gottfried Himmler, Geert Mudde, Anton Bauer, Gerda Redl, Maximillian Woisetschlager
  • Patent number: 10087227
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: October 2, 2018
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang
  • Patent number: 10080785
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: September 25, 2018
    Assignee: NOVOZYMES BIOPHARMA DK A/S
    Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
  • Patent number: 10077290
    Abstract: Internally cross-linked peptides useful for interfering with Respiratory Syncytial Virus (RSV) infection is based on RSV-F protein. These peptides are capable of reducing infection in cellular and animal models.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: September 18, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Gregory H. Bird
  • Patent number: 10017555
    Abstract: The present invention provides an anthropogenic glucagon-like peptide-1 (GLP-1) recombinant protein molecule fused with an anthropogenic immunoglobulin subtype (IgG2) Fc section and a preparation method and purpose thereof. The fusion protein has the biological activity of GLP-1, and also has a significantly prolonged half-life in vivo. The fusion protein can be used to treat type II diabetes, obesity, and other diseases that are treated by decreasing serum glucose, suppressing gastrointestinal motility, and emptying or suppressing food intake.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: July 10, 2018
    Assignee: Genor Biopharma Co., Ltd
    Inventors: Joe Zhou, Qing Zhou, Rulei Chen, Shu Shi, Weihong Nian, Hongbin Yan
  • Patent number: 9908918
    Abstract: Engineered orange-red fluorescent proteins with enhanced fluorescent properties, obtained by mutagenesis of mNeptune2, are disclosed. In particular, the invention relates to engineered orange-red fluorescent proteins excitable with cyan light having increased emission intensity and their use in bioluminescent resonance energy transfer systems and fluorescence and bioluminescence imaging.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: March 6, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael Lin, Jun Chu, Younghee Oh
  • Patent number: 9856311
    Abstract: Libraries of immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: January 2, 2018
    Assignee: F-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H
    Inventors: Florian Ruker, Gottfried Himmler, Gordana Wozniak-Knopp
  • Patent number: 9850289
    Abstract: The present invention is generally directed to fusion proteins containing a targeting sequence that targets the fusion protein to the exosporium of a Bacillus cereus family member. The invention also relates to recombinant Bacillus cereus family members expressing such fusion proteins and formulations containing the recombinant Bacillus cereus family members expressing the fusion proteins. Methods for stimulating plant growth, for protecting plants from pathogens, and for enhancing stress resistance in a plant by applying the recombinant Bacillus cereus family members or the formulations to plants or a plant growth medium are also described. The invention also relates to methods for immobilizing spores of a recombinant Bacillus cereus family member expressing a fusion protein on plants.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: December 26, 2017
    Assignee: Spogen Biotech Inc.
    Inventors: Brian Thompson, Katie Thompson
  • Patent number: 9821039
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acid vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: November 21, 2017
    Assignee: ALBUMEDIX A/S
    Inventors: David J. Ballance, Darrell Sleep
  • Patent number: RE47528
    Abstract: We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: July 23, 2019
    Assignee: B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG
    Inventors: Frank Niehaus, Jürgen Eck, Renate Schulze, Michael Krohn